Voltage-gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells

July 2014
Oncology Letters;2014, Vol. 8 Issue 1, p345
Academic Journal
Voltage-gated sodium channels (VGSCs) are expressed not only in excitable cells but also in numerous metastatic cells, particularly in certain types of cancer cells. In some types of cancer, including prostate cancer, the expression of VGSCs is associated with cancer migration, invasion and metastasis in vivo. However, the detailed expression profiles of VGSC α subunits in normal human prostate, in prostatic hyperplasia and prostatic cancer remain controversial. In the present study, quantitative polymerase chain reaction was used to systematically detect all subtypes of VGSC α subunits in normal human prostate, benign prostatic hyperplasia (BPH) and prostate cancer cells. The expression profile of VGSC α subunits was observed to differ between these cell types. Nav1.5 was the major isoform expressed in normal human prostate tissue, while Nav1.5 and Nav1.2 were the predominant isoforms in BPH tissue. However, in PC-3 and LNCaP cells, two typical prostate cancer cell lines, Nav1.6 and Nav1.7 were abundantly expressed. By comparing the relative expression levels of Nav1.5, Nav1.6 and Nav1.7 in these cells, the mRNA levels of Nav1.6 and Nav1.7 were identified to be 6- to 27-fold higher in PC-3 and LNCaP cells than in either normal or BPH samples (P<0.05); however, Nav1.5 mRNA levels were relatively lower compared with those of Nav1.6 or Nav1.7 in all cells analyzed. To confirm whether Nav1.6 and Nav1.7 expression in cancer cells was functional, a patch-clamp technique was used to record whole-cell currents. A tetrodotoxin-sensitive sodium current was successfully recorded in PC-3 cells, but not in LNCaP cells. It was concluded that although all types of VGSC α subunits exhibited low expression levels in normal prostate and BPH cells, both Nav1.6 and Nav1.7 were significantly upregulated in the prostate cancer cell lines, suggesting these subtypes may be potential diagnostic markers and therapeutic targets for certain types of prostate cancer in humans.


Related Articles

  • What is Benign Prostatic Hyperplasia?  // Tennessee Tribune;12/17/2015, Vol. 26 Issue 51, p11B 

    The article offers information on the Benign prostatic hyperplasia (BPH) that is part of the aging process in men, caused by changes in hormone balance and in cell growth, along with its symptoms and diagnosis.

  • Community-based research on the benign prostatic hyperplasia prevalence rate in Korean rural area. Hyeok Jun Goh; Shin Ah Kim; Ji Won Nam; Bo Youl Choi; Hong Sang Moon // Korean Journal of Urology;Jan2015, Vol. 56 Issue 1, p68 

    Purpose: We investigated the prevalence rate of benign prostatic hyperplasia (BPH) among Korean males in a rural area through a cross-sectional, community-based epidemiologic survey and analyzed the correlation with epidemiologic factors. Materials and Methods: A total of 779 males who lived in...

  • High Milk Consumption Does Not Affect Prostate Tumor Progression in Two Mouse Models of Benign and Neoplastic Lesions. Bernichtein, Sophie; Pigat, Natascha; Capiod, Thierry; Boutillon, Florence; Verkarre, Virginie; Camparo, Philippe; Viltard, Mélanie; Méjean, Arnaud; Oudard, Stéphane; Souberbielle, Jean-Claude; Friedlander, Gérard; Goffin, Vincent // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Epidemiological studies that have investigated whether dairy (mainly milk) diets are associated with prostate cancer risk have led to controversial conclusions. In addition, no existing study clearly evaluated the effects of dairy/milk diets on prostate tumor progression, which is clinically...

  • The clinical relevance of the correlation of NM 23-H1 expression with PAP, PSA and Androgen Receptors in patients with Prostate Cancer and BPH. BUDAK, MEHMET; ORHAN, DİCLEHAN; TULUNAY, ÖZDEN; GÖĞÜŞ, ORHAN // Turkish Journal of Cancer;2009, Vol. 39 Issue 4, p138 

    We investigate the correlation of the tissue expressions of NM23-H1, androgen receptor, serum PSA and PAP in patients with prostate cancer and benign prostatic hyperplasia to search for the possible relevance for the prognosis. Seventy-five patients were included to study, of these, 55 were...

  • Comparing Performance of Different Neural Networks for Early Detection of Cancer from Benign Hyperplasia of Prostate. GHADERZADEH, Mustafa; FEIN, Rebecca; STANDRING, Arran // Applied Medical Informatics;Sep2013, Vol. 33 Issue 3, p45 

    Prostate cancer is one of the most common types of cancer found in men. Presenting a classifier in order classifies between Prostate Cancer (PCa) and benign hyperplasia of prostate (BPH), has been great challenge among computer experts and medical specialists. There are a number of techniques...

  • PSA-based parameters and their diagnostic performances in patients with prostate cancer and benign prostatic hyperplasia. Koçer, Derya; Karakükcü, Çiğdem; Karaman, Hatice; Taşdemir, Arzu; Ergül, Mehmet Ali // Turkish Journal of Biochemistry / Turk Biyokimya Dergisi;2013, Vol. 38 Issue 1, p37 

    Objective: The aim of this study is to evaluate the diagnostic performance of PSA-based parameters in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and to determine the relation between serum PSA and histopathological grade in PCa. Methods: This retrospective study includes data...

  • Coexisting Prostate Cancer Found at the Time of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: Predicting Its Presence and Grade in Analyzed Tissue. Bhojani, Naeem; Boris, Ronald S.; Monn, M. Francesca; Mandeville, Jessica A.; Lingeman, James E. // Journal of Endourology;Jan2015, Vol. 29 Issue 1, p41 

    Objective: To determine the incidence of prostate cancer identified on holmium laser enucleation of the prostate (HoLEP) specimens and evaluate variables associated with prostate cancer identification. Patients and Methods: All patients undergoing HoLEP between 1998 and 2013 were identified....

  • Inflammation: an important parameter in the search of prostate cancer biomarkers. Bergamini, Stefania; Bellei, Elisa; Bonetti, Luca Reggiani; Monari, Emanuela; Cuoghi, Aurora; Borelli, Francesco; Sighinolfi, Maria Chiara; Bianchi, Giampaolo; Ozben, Tomris; Tomasi, Aldo // Proteome Science;2014, Vol. 12 Issue 1, p1 

    Background: A more specific and early diagnostics for prostate cancer (PCa) is highly desirable. In this study, being inflammation the focus of our effort, serum protein profiles were analyzed in order to investigate if this parameter could interfere with the search of discriminating proteins...

  • New technique for prostate volume assessment. Habes, Mohamad; Bahr, Jeanette; Schiller, Thilo; Kühn, Jens-Peter; Hoppe, Laura; Burchardt, Martin; Hoffmann, Wolfgang // World Journal of Urology;Dec2014, Vol. 32 Issue 6, p1559 

    Purpose: The prostate-specific antigen density (PSAD) helps distinguish between benign prostatic hyperplasia (BPH) and prostate cancer. Accurate prostate volume (PV) assessment is necessary for PSAD calculation and both BPH diagnosis and treatment response monitoring; therefore, accurate PV...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics